Develop new microbiome immunotherapy! Vedanta C round raised $27 million.

Vedanta Biosciences is a clinical biotech company focused on developing a new class of therapies based on well-designed human bacterial complexes for the treatment of immuno-mediated diseases. Recently, the company announced that it had raised $27 million in round C financing, which included new and existing strategic and institutional investors including the Bill and Melinda Gates Foundation, Shishi Shiguibo, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and PureTech Health.
the proceeds of this round of financing will be used to advance the development of Vedanta's microbiome derivative candidate pipeline, including a Phase I/II study of VE416 for the treatment of food allergies, a Phase I/II study of VE800 and Opdivo combination therapies for the treatment of advanced or metastasis cancers, and a Phase II study of the recently launched VE303 treatment of relapsed Thyrobacteria (rCDI).
Vedanta is working on an innovative class of drugs that regulate the interaction between the body's microbiome and the immune system. Using its unique technology platform, Vedanta not only isolates a number of symbiotic strains in the human gut, but also sheds light on how the body's immune system responds to them. Some strains can suppress the body's immune response and may be used to treat autoimmune diseases such as inflammatory bowel disease (IBD), while others can stimulate the body's immune response and may help the body respond more strongly to infection or cancer.
, Vedanta has produced one of the largest and most diverse intestinal symbox cultures in the world. Vedanta's goal is to develop innovative drugs related to infectious diseases, inflammation, immune tolerance, and immuno-oncology through pharmacologically relevant characteristics of different strains, such as the ability to induce different types of immune responses, to reasonably combine different strains, and to use proprietary bioinficial tools and mathematical modeling to understand how to optimize the combination of strains.
unlike microbiome regulation with metabolites derived from a single strain or microbiome, Vedanta's human bacterial complex therapy aims to make robust and lasting therapeutic changes to the patient's gut microbiome. Unlike fecal transplantation or the use of fecal components, human bacterial combination therapy consists of explicit components produced from pure clone libraries, bypassing fecal feed materials that rely on direct sources and inconsistent compositions. In preclinical and clinical studies, this type of human bacterial complex as a new treatment is safe and well-to-toned, and has good pharmacogenics and pharmacodynamics in the human body.
Vedanta developed a human bacterial combination therapy, which is given as an oral capsule of freeze-dried bacteria powder, through which live bacteria travel along the gastrointestinal tract and are planted in the intestines, stimulating a range of immune responses, including immunomodulative responses (with the potential to treat autoimmune and allergic diseases) and immune-enhanced responses (with potential for cancer and vaccination).
, Vedanta has reached strategic partnerships with Johnson and Johnson, Shishi Shiguibao, Langton Medical Center in New York, Stanford University School of Medicine, and Leyden University Medical Center. (Bio Valley)